Completed PHASE1/PHASE2 INTERVENTIONAL 5-arm NCT02472795

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-response Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

Sponsor: Viatris Innovation GmbH

Conditions Systemic Lupus Erythematosus

Interventions Cenerimod Matching placebo

Updated 13 times since 2017 Last updated: Sep 16, 2025 Started: Jun 1, 2015 Primary completion: Jan 23, 2017 Completion: Feb 28, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Systemic Lupus Erythematosus and is currently completed. Viatris Innovation GmbH leads this study, which shows 13 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

13 versions recorded

Nov 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2025 — Nov 2025 [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2

▶ Show 8 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE1_PHASE2
Mar 2020 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

Phase: PHASE2 → PHASE1_PHASE2
Aug 2018 — Mar 2020 [monthly]

Completed PHASE2
Jun 2018 — Aug 2018 [monthly]

Completed PHASE2
Aug 2017 — Jun 2018 [monthly]

Completed PHASE2
Apr 2017 — Aug 2017 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Feb 2017 — Apr 2017 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Viatris Innovation GmbH

Data source: Viatris Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anniston, United States , Clearwater, United States , Kemerovo, Russia , Kursk, Russia , Minsk, Belarus , Omsk, Russia , Orenburg, Russia , Plovdiv, Bulgaria , Smolensk, Russia , Sofia, Bulgaria and 5 more locations